ES2183131T3 - Anticuerpos anti-cd18 utilizados contra el ictus cerebral. - Google Patents

Anticuerpos anti-cd18 utilizados contra el ictus cerebral.

Info

Publication number
ES2183131T3
ES2183131T3 ES97903790T ES97903790T ES2183131T3 ES 2183131 T3 ES2183131 T3 ES 2183131T3 ES 97903790 T ES97903790 T ES 97903790T ES 97903790 T ES97903790 T ES 97903790T ES 2183131 T3 ES2183131 T3 ES 2183131T3
Authority
ES
Spain
Prior art keywords
antibodies used
used against
against cerebral
cerebral ictus
ictus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97903790T
Other languages
English (en)
Inventor
Martin M Bednar
Cordell E Gross
G Roger Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Vermont
Genentech Inc
Original Assignee
University of Vermont
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Vermont, Genentech Inc filed Critical University of Vermont
Application granted granted Critical
Publication of ES2183131T3 publication Critical patent/ES2183131T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE UN METODO PARA MEJORAR EL RESULTADO CLINICO EN EL ATAQUE ISQUEMICO FOCAL EN UN MAMIFERO INCREMENTANDO EL FLUJO SANGUINEO CEREBRAL Y/O REDUCIENDO EL TAMAÑO DEL INFARTO, QUE IMPLICA LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UN ANTICUERPO ANTI CD18 AL MAMIFERO, SIN QUE SE HAYA RETIRADO LA OBSTRUCCION ARTERIAL.
ES97903790T 1996-01-23 1997-01-11 Anticuerpos anti-cd18 utilizados contra el ictus cerebral. Expired - Lifetime ES2183131T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58998296A 1996-01-23 1996-01-23

Publications (1)

Publication Number Publication Date
ES2183131T3 true ES2183131T3 (es) 2003-03-16

Family

ID=24360401

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97903790T Expired - Lifetime ES2183131T3 (es) 1996-01-23 1997-01-11 Anticuerpos anti-cd18 utilizados contra el ictus cerebral.

Country Status (13)

Country Link
EP (2) EP0877626B1 (es)
JP (1) JP4864175B2 (es)
AR (1) AR005535A1 (es)
AT (1) ATE222774T1 (es)
AU (1) AU724449B2 (es)
CA (1) CA2242414C (es)
DE (1) DE69714966T2 (es)
DK (1) DK0877626T3 (es)
ES (1) ES2183131T3 (es)
IL (1) IL125255A (es)
PT (1) PT877626E (es)
WO (1) WO1997026912A2 (es)
ZA (1) ZA97257B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
AU4000500A (en) * 1999-02-17 2000-09-04 Genentech Inc. Co-administration of a thrombolytic and an anti-cd18 antibody
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
WO2001070266A2 (en) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
EP1278538A4 (en) * 2000-03-18 2005-05-04 Millennium Pharm Inc ANTIBODIES BINDING TO CD18 AND INHIBITING STENOSE-RELATED DISORDERS
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
WO2005058251A2 (en) 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
CA2572098C (en) * 2004-06-30 2015-01-27 Mayo Foundation For Medical Education And Research B7-dc binding antibody
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
JP5361738B2 (ja) 2007-01-22 2013-12-04 ジェネンテック， インコーポレイテッド 多価電解質沈殿物及びタンパク質の精製
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
CN105315323A (zh) 2007-10-30 2016-02-10 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
ES2978373T3 (es) 2008-08-14 2024-09-11 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
MX2011002372A (es) 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
US20100190963A1 (en) 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
SG171764A1 (en) 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
EP3736338A1 (en) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
EP2571903B1 (en) 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
ES2809211T3 (es) 2011-07-08 2021-03-03 Emd Millipore Corp Filtros de profundidad mejorados para procesos biotecnológicos desechables
US10364268B2 (en) 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
RU2017139267A (ru) 2012-03-27 2019-02-12 Дженентек, Инк. Усовершенствованные способы выделения рекомбинантных белков
PL2849723T3 (pl) 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
WO2016007752A1 (en) 2014-07-09 2016-01-14 Genentech, Inc. Ph adjustment to improve thaw recovery of cell banks
CN109312299A (zh) 2016-03-29 2019-02-05 格尔托公司 蛋白质在具有0.5:1至10:1的周质体积与细胞质体积比的革兰氏阴性菌中的表达
KR102579836B1 (ko) 2016-12-22 2023-09-15 제넨테크, 인크. 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
RS65472B1 (sr) 2018-07-03 2024-05-31 Bristol Myers Squibb Co Postupak proizvodnje rekombinantnih proteina
US12415980B2 (en) 2018-10-10 2025-09-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
AU2020254582B2 (en) 2019-04-01 2025-12-18 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
TW202104254A (zh) 2019-04-12 2021-02-01 美商格爾托公司 重組彈性蛋白及其生產
EP4007808A1 (en) 2019-08-01 2022-06-08 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
US12486525B2 (en) 2020-09-22 2025-12-02 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH06511156A (ja) * 1992-07-16 1994-12-15 イコス　コーポレイション 炎症性疾患状態に関連する症状の緩和
WO1994012214A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18

Also Published As

Publication number Publication date
AU724449B2 (en) 2000-09-21
ZA97257B (en) 1998-07-14
EP0877626B1 (en) 2002-08-28
JP2000517289A (ja) 2000-12-26
WO1997026912A3 (en) 1997-10-09
AU1827397A (en) 1997-08-20
JP4864175B2 (ja) 2012-02-01
WO1997026912A2 (en) 1997-07-31
EP1297847A2 (en) 2003-04-02
IL125255A0 (en) 1999-03-12
EP0877626A2 (en) 1998-11-18
CA2242414A1 (en) 1997-07-31
DK0877626T3 (da) 2002-12-30
PT877626E (pt) 2003-01-31
DE69714966T2 (de) 2003-04-24
CA2242414C (en) 2012-01-03
IL125255A (en) 2002-02-10
EP1297847A3 (en) 2003-05-07
DE69714966D1 (de) 2002-10-02
ATE222774T1 (de) 2002-09-15
AR005535A1 (es) 1999-06-23

Similar Documents

Publication Publication Date Title
WO1997026912A3 (en) Anti-cd18 antibodies for use against stroke
KR910004187A (ko) 세트랄린을 사용한 조기사정의 치료방법
ES2160631T3 (es) Composiciones de retinoides para aplicacion topica.
AR004790A1 (es) Reduccion del crecimiento del pelo
CA2245125A1 (fr) Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
ATE196078T1 (de) Transparente, schnell freisetzende zubereitungen von nichtsteroidalen analgetica
BR9705207A (pt) Anel de vedação metálico para junta tubular.
DK0625050T3 (da) TGF-BETA til forbedring af regenerering af nervevæv
ES2195151T3 (es) Dispositivo de mejora de aporte o de muestreo de agentes transdermicos.
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
DE69232150D1 (de) Behandlung von Augenhochdruck mit Betablockern und Prostansäurederivaten
DK0665749T3 (da) Sammensætning til behandling af Parkinsons sygdom
EE03223B1 (et) Kiiretoimelist dihüdropüridiinühendit sisaldav farmatseutiline emulsioon vererõhu alandamiseks ja selle valmistamise protsess
ES2102424T3 (es) Composicion de eliminacion de tapones queratosicos.
ECSP941082A (es) Procedimiento para la preparacion de la sal sodica cristalina adhidra de 5- cloro-3 (2-tenoli)-2- oxindol-1 carboxamida
NO933000L (no) Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer
KR960033452A (ko) 시신경 질환의 치료를 위한 프로스타노산 화합물
FR2413084A1 (fr) Composition cosmetique pour le demaquillage des yeux
RU97120710A (ru) Способ увеличения скорости кровотока глазного нерва и сетчатки глаза
DE69827295D1 (de) Kombination von einem den retinoinsäure metabolismus blockierenden arzneimittel und einem tocopherol
GB1495289A (en) Pharmaceutically active proteinaceous compounds
SE8801710D0 (sv) New ophtalmological composition of matter
GB9227123D0 (en) Method
MY8700934A (en) Pharmaceutical compositions comprising 7,8-dihydroxy-i(hydroxyphenyl)-2,3,4,5-tetrahydro-ih-3-benzazepine derivatives and a beta-adrenergic blocking compound